Related Experiment Video
Updated: Jul 19, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Neuroprotective therapy in Parkinson disease
1Institute of Neurology, Ruijin Hospital, Shanghai 2nd Medical University, Shanghai, China.
American Journal of Therapeutics
|September 22, 2006
Summary
Recent advances in Parkinson disease (PD) biology are driving the development of new therapies. These novel treatments aim to protect neurons and modify the disease, offering hope for a future cure.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Parkinson disease (PD) understanding has significantly advanced.
- Therapeutic focus shifts from symptom relief to disease modification and neuroprotection.
Purpose of the Study:
- To review novel therapeutic strategies for Parkinson disease.
- To explore treatments targeting disease mechanisms and neuroprotection.
Main Methods:
- Review of preclinical experiments and clinical trials.
- Investigation of gene-targeting molecules, neurotrophic factors, and novel dopamine agonists.
- Evaluation of antioxidant, anti-inflammatory, and anti-apoptotic agents.
Main Results:
- Multiple novel therapeutic approaches are under investigation.
- Emerging treatments show potential for protecting dopaminergic neurons.
- Studies indicate a promising future for Parkinson disease treatment.
Conclusions:
- Advances in PD biology offer new therapeutic avenues.
- Novel therapies aim to halt or reverse disease progression.
- Future research holds promise for a potential cure for Parkinson disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...